Daewon Pharmaceutical Co. Ltd. (003220) - Total Assets
Based on the latest financial reports, Daewon Pharmaceutical Co. Ltd. (003220) holds total assets worth ₩573.33 Billion KRW (≈ $388.54 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Daewon Pharmaceutical Co. Ltd. cash conversion from operations for how efficiently the company converts equity into cash flow.
Daewon Pharmaceutical Co. Ltd. - Total Assets Trend (2011–2025)
This chart illustrates how Daewon Pharmaceutical Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See Daewon Pharmaceutical Co. Ltd. share price for real-time trading data and today's change.
Daewon Pharmaceutical Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Daewon Pharmaceutical Co. Ltd.'s total assets of ₩573.33 Billion consist of 41.8% current assets and 58.2% non-current assets. Explore working capital to net assets of Daewon Pharmaceutical Co. Ltd. to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.7% |
| Accounts Receivable | ₩77.12 Billion | 12.6% |
| Inventory | ₩97.83 Billion | 15.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩56.48 Billion | 9.2% |
| Goodwill | ₩6.00 Billion | 1.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Daewon Pharmaceutical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daewon Pharmaceutical Co. Ltd.'s current assets represent 41.8% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2025, down from 12.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 15.9% of total assets.
Daewon Pharmaceutical Co. Ltd. Competitors by Total Assets
Key competitors of Daewon Pharmaceutical Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
|
Henan Taloph Pharmaceutical Stock Co Ltd
SHG:600222
|
China | CN¥3.68 Billion |
Daewon Pharmaceutical Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.20 | 1.97 |
| Quick Ratio | 0.62 | 0.65 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩25.69 Billion | ₩41.51 Billion | ₩84.38 Billion |
Daewon Pharmaceutical Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Daewon Pharmaceutical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.64 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | ₩613.65 Billion |
| Market Capitalization | $118.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daewon Pharmaceutical Co. Ltd.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Daewon Pharmaceutical Co. Ltd.'s assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Daewon Pharmaceutical Co. Ltd. (2011–2025)
The table below shows the annual total assets of Daewon Pharmaceutical Co. Ltd. from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩613.65 Billion ≈ $415.86 Million |
+5.19% |
| 2024-12-31 | ₩583.39 Billion ≈ $395.35 Million |
+14.84% |
| 2023-12-31 | ₩508.00 Billion ≈ $344.26 Million |
+12.00% |
| 2022-12-31 | ₩453.55 Billion ≈ $307.36 Million |
+5.58% |
| 2021-12-31 | ₩429.58 Billion ≈ $291.12 Million |
+28.15% |
| 2020-12-31 | ₩335.21 Billion ≈ $227.17 Million |
+2.35% |
| 2019-12-31 | ₩327.53 Billion ≈ $221.96 Million |
+18.91% |
| 2018-12-31 | ₩275.44 Billion ≈ $186.66 Million |
+21.23% |
| 2017-12-31 | ₩227.20 Billion ≈ $153.97 Million |
+5.83% |
| 2016-12-31 | ₩214.68 Billion ≈ $145.49 Million |
+10.23% |
| 2015-12-31 | ₩194.75 Billion ≈ $131.98 Million |
+7.82% |
| 2014-12-31 | ₩180.62 Billion ≈ $122.40 Million |
+12.79% |
| 2013-12-31 | ₩160.14 Billion ≈ $108.52 Million |
+8.85% |
| 2012-12-31 | ₩147.13 Billion ≈ $99.70 Million |
+4.80% |
| 2011-12-31 | ₩140.39 Billion ≈ $95.14 Million |
-- |
About Daewon Pharmaceutical Co. Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more